Review Article
Volume 9 Issue 1 - 2022
Revisiting Anemia in Heart Failure
Mohit Singh Tandon1* and Vineeta Singh Tandon2
1Consultant Non Invasive Cardiology , MAX Smart Hospital, saket, Delhi
2Consultant Internal Medicine ,PSRI Hospital, Sheikh Sarai, Delhi
*Corresponding Author: Mohit Singh Tandon, Non Invasive Cardiology, Max SMART Hospital, Saket, India.
Received: October 19, 2021; Published: January 27, 2022




Abstract

Anemia in heart failure is associated with decreased effort tolerance and increased mortality. The etiology is multifactorial including decreased erythropoietin production owing to renal dysfunction, marrow defects, drugs, and nutritional deficiencies mainly iron. Modalities of treatment in anemia have been studied intensively. Treatment with ESAs has been found to increase hemoglobin levels but without much improvement in clinical outcomes and with more adverse events like thromboembolic and ischemic strokes. Hence the routine use of ESA is not recommended. Whether anemia is the marker of the severity of heart failure or it is a therapeutic target is yet unclear. Intravenous Iron administration in patients with heart failure with iron deficiency improves symptoms and exercise capacity but long-term safety data is still awaited.

Keywords: Anemia; Heart Failure

References

  1. Beverborg NG., et al. “Erythropoietin in the general population: Reference ranges and clinical, biochemical and genetic correlates”. PLoS One (2015): e0125215.
  2. Groenveld HF., et al. “Anemia and Mortality in Heart Failure Patients. A Systematic Review and Meta-Analysis”. Journal of the American College of Cardiology10 (2008): 818-827.
  3. Tang WHW., et al. “Evaluation and Long-Term Prognosis of New-Onset, Transient, and Persistent Anemia in Ambulatory Patients With Chronic Heart Failure”. Journal of the American College of Cardiology5 (2008): 569-576.
  4. Waldum B., et al. “Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction: Results from the Norwegian heart failure registry”. Journal of the American College of Cardiology4 (2012): 371-378.
  5. Tang Y Da and Katz SD. “The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes”. Heart Failure Reviews4 (2008): 387-392.
  6. O’Meara E., et al. “Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure - Results of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program”. Circulation7 (2006): 986-994.
  7. Ezekowitz JA., et al. “Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure”. Circulation2 (2003): 223-225.
  8. Anand IS and Gupta P. “Anemia and Iron Deficiency in Heart Failure”. Circulation1 (2018): 80-98.
  9. Horwich TB., et al. “Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure”. Journal of the American College of Cardiology11 (2002): 1780-1786.
  10. Weiss G and Goodnough LT. “Anemia of chronic disease”. New England Journal of Medicine10 (2005): 1011-1023.
  11. Grote Beverborg N., et al. “Anemia in Heart Failure: Still Relevant?” JACC: Heart Failure 6 (2018): 201-208.
  12. Van Der Meer P., et al. “Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure”. Circulation 12 (2005): 1743-1747.
  13. Ishani A., et al. “Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction”. Journal of the American College of Cardiology 3 (2005): 391-399.
  14. Komajda M., et al. “The impact of new onset anaemia on morbidity and mortality in chronic heart failure: Results from COMET”. European Heart Journal 12 (2006): 1440-1446.
  15. Anand IS., et al. “Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure”. Circulation 2 (1989): 299-305.
  16. Anand IS., et al. “Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure: Results From Val-HeFT”. ACC Current Journal Review8 (2005): 1127-1127.
  17. Caramelo C., et al. “Anemia in Heart Failure: Pathophysiology, Pathogenesis, Treatment, and Incognitae”. Revista Española de Cardiología (2007).
  18. Anand IS., et al. “Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones”. Heart4 (1993): 357-362.
  19. Kao DP., et al. “Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (Public discharge data from California 2000-2006)”. The American Journal of Cardiology1 (2011): 69-73.
  20. Garty M., et al. “Blood transfusion for acute decompensated heart failure-friend or foe?” American Heart Journal 4 (2009): 653-658.
  21. Mazer CD., et al. “Restrictive or liberal red-cell transfusion for cardiac surgery”. The New England Journal of Medicine (2017).
  22. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease”. Kidney International Supplements4 (2012): 279-335.
  23. Qaseem A., et al. “Treatment of anemia in patients with heart disease: A clinical practice guideline from the American College of Physicians”. Annals of Internal Medicine (2013).
  24. Swedberg K., et al. “Treatment of anemia with darbepoetin alfa in systolic heart failure”. The New England Journal of Medicine (2013).
  25. Yancy CW., et al. “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure”. Journal of the American College of Cardiology (2017).
  26. Lewis GD., et al. “Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure”. Circulation: Heart Failure5 (2016): e000345.
  27. Ponikowski P., et al. “Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency”. European Heart Journal11 (2015): 657-668.
  28. Van Veldhuisen DJ., et al. “Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency”. In: Circulation15 (2017): 1374-1383.
  29. Grote Beverborg N and Van der Meer P. “Definition of iron deficiency based on the gold standard of bone marrow iron staining and treatment effect of ferric carboxymaltose in heart failure patients (abstr.)”. European Journal of Heart Failure2 (2017): e004519.
  30. Ponikowski P., et al. “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution”. European Journal of Heart Failure (2016).
  31. Vadhan-Raj S., et al. “A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia”. Journal of Hematology and Oncology1 (2017): 73.
  32. Van Eijk LT., et al. “Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans”. Blood17 (2014): 2643-2646.
  33. Anker SD., et al. “Ferric carboxymaltose in patients with heart failure and iron deficiency”. The New England Journal of Medicine (2009).
  34. Havill J., et al. “Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in Patients with End-Stage Kidney Disease on Hemodialysis”. American Society of Nephrology (2015): 310A-311A.
  35. Paulson RF. “Targeting a new regulator of erythropoiesis to alleviate anemia”. Nature Medicine4 (2014): 334-335.
  36. Iancu-Rubin C., et al. “Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap”. Experimental Hematology2 (2013): 155-166.
Citation: Mohit Singh Tandon and Vineeta Singh Tandon. “Revisiting Anemia in Heart Failure”. EC Cardiology 9.1 (2022): 03-11.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 15, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.